Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Mar 24, 2025
REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended December 31, 2024, and provided a business update.
0.323
+0.03 (+8.39%)
Find more stocks in the Stock Screener
BOLT Latest News and Analysis
3 days ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
